Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of Stock

VolitionRx Limited (NYSE:VNRX - Get Free Report) Director Guy Archibald Innes acquired 20,000 shares of VolitionRx stock in a transaction dated Tuesday, June 3rd. The shares were purchased at an average price of $0.54 per share, with a total value of $10,800.00. Following the acquisition, the director now owns 888,689 shares of the company's stock, valued at approximately $479,892.06. This trade represents a 2.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

VolitionRx Price Performance

VNRX traded up $0.01 during trading on Thursday, hitting $0.58. 163,779 shares of the stock traded hands, compared to its average volume of 188,639. VolitionRx Limited has a twelve month low of $0.40 and a twelve month high of $0.90. The company has a market cap of $59.44 million, a price-to-earnings ratio of -1.60 and a beta of 1.07. The business has a 50 day moving average price of $0.50 and a 200 day moving average price of $0.57.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in VNRX. Two Sigma Securities LLC acquired a new position in VolitionRx during the fourth quarter valued at approximately $29,000. Millennium Management LLC acquired a new position in VolitionRx during the fourth quarter valued at approximately $36,000. Northern Trust Corp raised its position in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after purchasing an additional 28,579 shares in the last quarter. Finally, Lagoda Investment Management L.P. raised its position in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on VNRX. Wall Street Zen began coverage on VolitionRx in a research note on Thursday, May 15th. They issued a "sell" rating for the company. HC Wainwright began coverage on VolitionRx in a research note on Tuesday, April 8th. They issued a "buy" rating and a $2.50 price target for the company. Finally, D. Boral Capital reiterated a "buy" rating and issued a $5.00 price target on shares of VolitionRx in a research note on Wednesday, April 30th.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.